Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have… read more.
Novo Nordisk announced headline results from STEP UP, a phase IIIb trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous… read more.
Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that Eli Lilly Japan received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour… read more.
A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests… read more.
NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.
The speed at which people walk can provide insights into health, extending beyond mere mobility, according to experts in Japan. Past studies have suggested that a slow walking… read more.
Eli Lilly and Company announced the FDA approved Zepbound (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound… read more.
A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health found that more than half of calories consumed at home by adults in… read more.
An investigation published by The BMJ today reveals widespread influence of food and drink brands in schools and nurseries – through breakfast clubs, nutrition guidance, and healthy eating campaigns –… read more.
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a… read more.
A new study by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with researchers at Harvard T.H. Chan School of Public… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
